The Chinese drug administration approved China Resources Double-Crane Pharmaceutical's (SHA:600062) supplementary application to increase the specifications of sugammadex sodium injection, according to a Shanghai Stock Exchange filing on Wednesday.
The specification of the drug will be raised to 5 milliliters:500 milligrams.
The drug is used for the reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults and for the reversal of rocuronium-induced blockade in children and adolescents, the pharmaceutical company said.
A new drug approval number that will be valid for 12 months will be issued.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.